4.5 Article

Exercise as an Augmentation Treatment for Nonremitted Major Depressive Disorder: A Randomized, Parallel Dose Comparison

期刊

JOURNAL OF CLINICAL PSYCHIATRY
卷 72, 期 5, 页码 677-684

出版社

PHYSICIANS POSTGRADUATE PRESS
DOI: 10.4088/JCP.10m06743

关键词

-

资金

  1. Agency for Healthcare Research and Quality
  2. Corcept Therapeutics
  3. Cyberonics
  4. Merck
  5. NARSAD
  6. National Institute of Mental Health (NIMH)
  7. National Institute on Drug Abuse
  8. Novartis
  9. Pharmacia Upjohn
  10. Predix (EPIX)
  11. Solvay
  12. Targacept
  13. Abbott
  14. Abdi Ibrahim
  15. Akzo (Organon)
  16. AstraZeneca
  17. Axon Advisors
  18. Bristol-Myers Squibb
  19. Cephalon
  20. CME Institute of Physicians Postgraduate Press
  21. Eli Lilly
  22. Evotec
  23. Fabre-Kramer, Forest
  24. GlaxoSmithKline
  25. Janssen
  26. Johnson Johnson
  27. Lundbeck
  28. Meade Johnson
  29. MedAvante
  30. Medtronic
  31. Neuronetics
  32. Otsuka
  33. Pamlab
  34. Parke-Davis
  35. Pfizer
  36. PGxHealth
  37. Rexahn
  38. Sepracor
  39. Shire Development
  40. Takeda
  41. VantagePoint
  42. Wyeth-Ayerst
  43. National Institutes of Health
  44. National Cancer Institute [R44CA139607]
  45. University of Michigan
  46. Brain Resource
  47. Otsuka Pharmaceuticals
  48. Guilford Publications
  49. The University of Texas Southwestern Medical Center at Dallas

向作者/读者索取更多资源

Objective: Most patients with major depressive disorder (MDD) require second-step treatments to achieve remission. The TReatment with Exercise Augmentation for Depression (TREAD) study was designed to test the efficacy of aerobic exercise as an augmentation treatment for MDD patients who had not remitted with antidepressant treatment. Method: Eligible participants in this randomized controlled trial were sedentary individuals (men and women aged 18-70 years) diagnosed with DSM-IV nonpsychotic MDD who had not remitted with selective serotonin reuptake inhibitor (SSRI) treatment. Participants were recruited through physician referrals and advertisements. A total of 126 participants were randomized to augmentation treatment with either 16 kcal per kg per week (KKW) or 4 KKW of exercise expenditure for 12 weeks while SSRI treatment was held constant. Supervised sessions were conducted at The Cooper Institute, Dallas, Texas, with additional home-based sessions as needed to fulfill the weekly exercise prescription. The primary outcome was remission (as determined by a score <= 12 on the Inventory of Depressive Symptomatology, Clinician-Rated). The study took place between August 2003 and August 2007. Results: There were significant improvements over time for both groups combined (F-1,F-121=39.9, P<.0001), without differential group effect (group effect: F-1,F-134=3.2, P=.07; group-by-time effect: F-1,F-119=3.8, P=.06). Adjusted remission rates at week 12 were 28.3% versus 15.5% for the 16-KKW and 4-KKW groups, respectively, leading to a number needed to treat (NNT) of 7.8 for 16 KKW versus 4 KKW. Men, regardless of family history of mental illness, and women without a family history of mental illness had higher remission rates by week 12 with higher-dose (women, 39.0%; men, 85.4%) than with lower-dose exercise (women, 5.6%; men, 0.1%) (women: t(95)=2.1, P=.04; men: t(88)=5.4, P<.0001) (NNT: women, 3.0; men, 1.2). Conclusions: There was a trend for higher remission rates in the higher-dose exercise group (P<.06), with a clinically meaningful NNT of 7.8 in favor of the high exercise dose. Significant differences between groups were found when the moderating effects of gender and family history of mental illness were taken into account and suggest that higher-dose exercise may be better for all men and for women without a family history of mental illness.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据